Application of lnc-RNF219-3: 1 and related biological element thereof in deep venous thrombosis diagnosis and treatment

By studying the regulation of the lnc-RNF219-3:1/miR-93-5p/Tim-4 signaling axis, the problems of low accuracy and great side effects in the diagnosis and treatment of deep venous thrombosis were solved, and the diagnosis marks of high accuracy were provided The drug and potential therapeutic targets significantly inhibit thrombosis and improve the clinical diagnosis and treatment effect of DVT.

CN118957052APending Publication Date: 2024-11-15SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411264628.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-10
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

The prior art has problems with low accuracy, large side effects and frequent post-thrombotic syndromes in the diagnosis and treatment of deep venous thrombosis (DVT), and lacks effective biomarkers and targeted treatment methods.

Method used

The study found that the lnc-RNF219-3:1/miR-93-5p/Tim-4 signaling axis is involved in the pathogenesis of deep venous thrombosis. It inhibits miR-93-5p by overexpressing lnc-RNF219-3:1 and indirectly upregulates Tim- 4 expression, thereby inhibiting thrombosis, providing new biomarkers and targets, and developing screening, diagnostic, monitoring and treatment systems for deep venous thrombosis.

Benefits of technology

Through the regulation of the lnc-RNF219-3:1/miR-93-5p/Tim-4 signaling axis, the thrombosis process is significantly inhibited, providing high-accurate diagnostic markers and potential therapeutic targets, and improving the DVT Clinical diagnosis and treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118957052A_ABST
    Figure CN118957052A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of biological medicine and molecular biology, and particularly relates to application of lnc-RNF219-3: 1 and related biological elements thereof in deep vein thrombosis diagnosis and treatment. The invention discloses the pathogenesis of deep vein thrombosis participated by an lnc-RNF219-3: 1 / miR-93-5p / Tim-4 signal axis, and tests prove that the inhibition effect of targeted combination of miR-93-5p and Tim-4 is reduced by over-expressing lnc-RNF219-3: 1 through competitive combination of lnc-RNF219-3: 1 and Tim-4, so that the expression of Tim-4 is up-regulated, and the thrombosis process is inhibited. Meanwhile, the three markers have good diagnostic value for deep venous thrombosis, so that the three markers can be used as new biomarkers and targets for clinical diagnosis and treatment of deep venous thrombosis, and have good practical application value.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of biomedicine and molecular biology, and specifically relates to the application of lnc-RNF219-3:1 and related biological elements in the diagnosis and treatment of deep vein thrombosis. Background Art

[0002] The information disclosed in the background of the invention is only intended to enhance the understanding of the overall background of the invention and should not be necessarily regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] Deep vein thrombosis (DVT) is a common peripheral vascular disease, usually refers to the obstruction of venous blood return in the lower extremities, resulting in abnormal blood coagulation. DVT and its main complication pulmonary embolism, collectively known as venous thromboembolism, have become the third largest vascular disease after acute myocardial infarction and stroke, and are one of the leading causes of acute death and disability worldwide. Currently, deep vein ultrasound examination is the preferred method for diagnosing DVT, but it has low accuracy and is prone to misdiagnosis.

[0004] At present, conventional anticoagulation and thrombolysis are generally used to treat DVT. Although certain therapeutic effects are achieved, there are side effects such as bleeding, allergies, and liver and kidney damage. In addition, up to 50% of DVT patients will experience post-thrombotic syndrome, which seriously affects the quality of life of patients and brings great medical burden to patients and society. Therefore, it is urgent to find a new biomarker and biological targeted treatment method for DVT. Summary of the invention

[0005] In view of the deficiencies of the above-mentioned prior art, the purpose of the present invention is to apply lnc-RNF219-3:1 and its related biological elements in the diagnosis and treatment of deep vein thrombosis. Specifically, the present invention has found through research that the expression of the immunomodulatory molecule Tim-4 in DVT patients is significantly decreased. Studies have shown that miR-93-5p can regulate Tim-4 expression, and then through experiments, it has been verified that overexpression of lnc-RNF219-3:1 indirectly upregulates Tim-4 expression by inhibiting miR-93-5p, thereby inhibiting the thrombosis process. In short, the research of the present invention shows that the lnc-RNF219-3:1 / miR-93-5p / Tim-4 signaling axis is involved in the pathogenesis of deep vein thrombosis, and provides new biomarkers and targets for the clinical diagnosis and treatment of deep vein thrombosis. Based on the above research results, the present invention is completed.

[0006] Specifically, the technical solution of the present invention is as follows:

[0007] The first aspect of the present invention provides the use of a reagent for detecting the expression level of lnc-RNF219-3:1 and its related biological elements in the preparation of a product for screening, diagnosis, detection, monitoring or prognosis of deep vein thrombosis.

[0008] Among them, the lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

[0009] A second aspect of the present invention provides a system for screening, diagnosing, detecting, monitoring or prognosing deep vein thrombosis, the system comprising:

[0010] An acquisition module is configured to: obtain the expression level of lnc-RNF219-3:1 and its related biological elements in the test sample of the subject;

[0011] The evaluation module is configured to evaluate and judge the disease condition of the subject according to the subject's lnc-RNF219-3:1 and its related biological elements obtained by the acquisition module.

[0012] Among them, the lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

[0013] The sample to be tested can be a blood sample (such as peripheral blood) or a cell sample (such as peripheral blood mononuclear cell) of a subject.

[0014] The third aspect of the present invention provides the use of lnc-RNF219-3:1 and related biological elements as targets in the preparation and / or screening of deep vein thrombosis drugs.

[0015] Specifically, the effects of the candidate drug on lnc-RNF219-3:1 and its related biological elements before and after use can be used to determine whether the candidate drug can be used to prevent or treat deep vein thrombosis.

[0016] Specifically, the method for screening drugs for preventing or treating deep vein thrombosis includes:

[0017] 1) Treat the system expressing and / or containing lnc-RNF219-3:1 and its related biological elements with the candidate substance; set up a parallel control without the candidate substance treatment;

[0018] 2) After completing step 1), the expression level of the lnc-RNF219-3:1 and its related biological elements in the detection system; compared with the parallel control, if the expression amount of the lnc-RNF219-3:1 and its related biological elements in the system treated with the candidate substance is significantly downregulated or upregulated, the candidate substance can be used as a candidate drug for preventing or treating deep vein thrombosis.

[0019] The fourth aspect of the present invention provides the use of a substance that promotes the expression of lnc-RNF219-3:1 or increases its activity in any one or more of the following:

[0020] a) inhibiting the expression of miR-93-5p or preparing a product that inhibits the expression of miR-93-5p;

[0021] b) promoting the expression of Tim-4 or preparing a product that promotes the expression of Tim-4;

[0022] c) Inhibiting the expression of prothrombotic factors or preparing products that inhibit the expression of prothrombotic factors;

[0023] d) Products for the prevention and / or treatment of deep vein thrombosis.

[0024] Beneficial technical effects of one or more of the above technical solutions:

[0025] The above technical scheme reveals the pathogenesis of deep vein thrombosis involving the lnc-RNF219-3:1 / miR-93-5p / Tim-4 signaling axis. It has been verified by experiments that overexpression of lnc-RNF219-3:1 reduces the inhibitory effect of targeted binding of miR-93-5p and Tim-4 by competing with Tim-4 to bind miR-93-5p, thereby upregulating the expression of Tim-4 and inhibiting the thrombosis process. At the same time, the three have good diagnostic value for deep vein thrombosis, so they can be used as new biomarkers and targets for the clinical diagnosis and treatment of deep vein thrombosis, and have good practical application value. BRIEF DESCRIPTION OF THE DRAWINGS

[0026] The accompanying drawings in the specification, which constitute a part of the present invention, are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute improper limitations on the present invention.

[0027] Figure 1 The expression level of Tim-4 in peripheral blood mononuclear cells of healthy subjects and DVT patients in Example 2 of the present invention.

[0028] Figure 2 It is the macrophage-specific knockout mouse successfully constructed in Example 3 of the present invention; wherein A is the identification of different mouse genotypes, B is the ordinary PCR technology to verify the knockout effect of Tim-4 in different macrophages, and C is the western blot technology to verify the knockout effect of Tim-4 in different macrophages.

[0029] Figure 3The effect of macrophage-specific knockout of Tim-4 on DVT formation in Example 4 of the present invention; wherein A is the result of ultrasound detection of mice, B is the result of photographing isolated thrombi and spleen, and C is the result of hematoxylin-eosin staining of mouse thrombus and spleen tissue sections.

[0030] Figure 4 This is the result of ceRNA network analysis of lncRNA-miRNA-mRNA of target molecule Tim-4 based on the whole transcriptome sequencing results of peripheral blood mononuclear cells of healthy subjects and DVT patients in Example 5 of the present invention.

[0031] Figure 5 The expression level of miR-93-5p in peripheral blood mononuclear cells of healthy subjects and DVT patients in Example 7 of the present invention.

[0032] Figure 6 The effects of miR-93-5p on Tim-4 expression and thrombosis in Example 8 of the present invention; miR-93-5p was overexpressed (miR-93-5p mimics) and the expression of miR-93-5p (miR-93-5p inhibitor) was inhibited, and the transfection efficiency was first detected (A and D), and then the expression of Tim-4 in THP1 cells was detected (B and E), and finally the expression changes of prothrombotic factors in HUVEC cells in this co-culture system were detected (C and F).

[0033] Figure 7 It is the expression level of lnc-RNF219-3:1 in peripheral blood mononuclear cells of healthy people and DVT patients in Example 9 of the present invention.

[0034] Figure 8 The effect of lnc-RNF219-3:1 overexpression on Tim-4, miR-93-5p and thrombosis in Example 10 of the present invention; wherein, THP1 cells were transfected with lnc-RNF219-3:1 overexpression plasmid, and the transfection efficiency was first detected (A), and then its effect on the expression of Tim-4 (B) and miR-93-5p (C) was detected, and finally the expression changes of prothrombotic factors in HUVEC in this co-culture system were detected (D).

[0035] Fig. 9The rescue experiment results in Example 11 of the present invention, that is, the effects of simultaneous overexpression of lnc-RNF219-3:1 and miR-93-5p mimics on Tim-4 expression and thrombosis; wherein, firstly, the transfection efficiency of lnc-RNF219-3:1 and miR-93-5p mimics was detected after overexpression (A and B), and then the effect of simultaneous overexpression of lnc-RNF219-3:1 and miR-93-5p mimics on Tim-4 expression was detected, and finally, the effect on the expression of prothrombotic factors in HUVEC cells in this co-culture system was detected (D).

[0036] Fig.10 This is the ROC curve for evaluating the accuracy of Tim-4, miR-93-5p and lnc-RNF219-3:1 as diagnostic markers in Example 12 of the present invention; wherein A, B, and C are respectively the evaluation of the accuracy of predicting Tim-4, miR-93-5p and lnc-RNF219-3:1 as diagnostic markers for DVT patients. DETAILED DESCRIPTION

[0037] It should be noted that the following detailed descriptions are illustrative and are intended to provide further explanation of the present application. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present application belongs.

[0038] It should be noted that the terms used herein are only for describing specific embodiments and are not intended to limit the exemplary embodiments according to the present application. As used herein, unless the context clearly indicates otherwise, the singular form is also intended to include the plural form. In addition, it should be understood that when the terms "comprise" and / or "include" are used in this specification, it indicates the presence of features, steps, operations, devices, components and / or combinations thereof.

[0039] In a typical embodiment of the present invention, a reagent for detecting the expression level of any one or more of lnc-RNF219-3:1 and its related biological elements is provided for use in the preparation of products for screening, (auxiliary) diagnosis, detection, monitoring or prognosis of deep vein thrombosis.

[0040] Among them, the lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

[0041] Specifically, the present invention has found through research that lnc-RNF219-3:1 is significantly downregulated in DVT patients, miR-93-5p is upregulated in DVT, and Tim-4 is downregulated in DVT patients. Mechanistically, overexpression of lnc-RNF219-3:1 indirectly upregulates Tim-4 expression by inhibiting miR-93-5p, reduces the expression of pro-thrombotic related proteins, and thus inhibits the thrombosis process. Therefore, the above-mentioned lnc-RNF219-3:1 and its related biological elements can be used as (auxiliary) diagnostic and prognostic markers and therapeutic targets for deep vein thrombosis.

[0042] The reagents for detecting any one or more expression levels of lnc-RNF219-3:1 and its related biological elements may include reagents for detecting the expression levels of genes encoding lnc-RNF219-3:1 and its related biological elements based on real-time fluorescence quantitative PCR, in situ hybridization, gene chips and gene sequencing, and / or reagents for detecting the expression levels of Tim-4 proteins based on immunodetection methods.

[0043] The products include but are not limited to primers, probes, (gene or protein) chips, nucleic acid membrane strips, detection kits, detection devices and detection equipment for detecting any one or more expression levels of lnc-RNF219-3:1 and its related biological elements, which are not specifically limited here.

[0044] In another embodiment of the present invention, a system for screening, diagnosing, detecting, monitoring or prognosing deep vein thrombosis is provided, the system comprising:

[0045] An acquisition module is configured to: obtain the expression level of any one or more of lnc-RNF219-3:1 and its related biological elements in the test sample of the subject;

[0046] The evaluation module is configured to evaluate and judge the disease condition of the subject according to the expression of any one or more of the subject's lnc-RNF219-3:1 and its related biological elements obtained by the acquisition module.

[0047] Among them, the lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

[0048] The sample to be tested can be a blood sample (such as peripheral blood) or a cell sample (such as peripheral blood mononuclear cell) of a subject.

[0049] In another specific embodiment of the present invention, the use of lnc-RNF219-3:1 and its related biological elements as targets in the preparation and / or screening of deep vein thrombosis drugs is provided.

[0050] Specifically, the effects of the candidate drug on lnc-RNF219-3:1 and its related biological elements before and after use can be used to determine whether the candidate drug can be used to prevent or treat deep vein thrombosis.

[0051] Specifically, the method for screening drugs for preventing or treating deep vein thrombosis includes:

[0052] 1) Treat the system expressing and / or containing lnc-RNF219-3:1 and its related biological elements with the candidate substance; set up a parallel control without the candidate substance treatment;

[0053] 2) After completing step 1), the expression level of the lnc-RNF219-3:1 and its related biological elements in the detection system; compared with the parallel control, if the expression amount of the lnc-RNF219-3:1 and its related biological elements in the system treated with the candidate substance is significantly downregulated or upregulated, the candidate substance can be used as a candidate drug for preventing or treating deep vein thrombosis.

[0054] Among them, the lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

[0055] More specifically, the specifics of step 2) are: if the expression of lnc-RNF219-3:1 is significantly upregulated, the expression of miR-93-5p is significantly downregulated and / or the expression of Tim-4 is significantly upregulated in the system treated with the candidate substance, then the candidate substance can be used as a candidate drug for preventing or treating deep vein thrombosis.

[0056] The system may be a subcellular system, a cell system, a solution system, a tissue system, an organ system or an animal system, and is not specifically limited herein.

[0057] In another specific embodiment of the present invention, there is provided a use of a substance for promoting the expression of lnc-RNF219-3:1 or increasing its activity in any one or more of the following:

[0058] a) inhibiting the expression of miR-93-5p or preparing a product that inhibits the expression of miR-93-5p;

[0059] b) promoting the expression of Tim-4 or preparing a product that promotes the expression of Tim-4;

[0060] c) Inhibiting the expression of prothrombotic factors or preparing products that inhibit the expression of prothrombotic factors;

[0061] d) Products for the prevention and / or treatment of deep vein thrombosis.

[0062] Among them, substances that promote the expression of lnc-RNF219-3:1 or increase its activity include but are not limited to overexpression plasmids for lnc-RNF219-3:1, overexpression viruses (such as lentiviruses, adeno-associated viruses, etc.) and substances required for the CRISPR-SAM system.

[0063] The prothrombotic factors include, but are not limited to, the prothrombotic proteins von Willebrand factor (VWF) and tissue factor (TF).

[0064] The product may be a drug or an experimental reagent for non-medical use, and the experimental reagent may be used for basic research.

[0065] According to the present invention, when the product is a medicine, the medicine further comprises at least one inactive pharmaceutical ingredient.

[0066] The inactive pharmaceutical ingredients may be carriers, excipients, diluents, etc. commonly used in pharmacy. Meanwhile, the inactive pharmaceutical ingredients such as carriers, excipients, diluents, etc. that may be included are well known in the art, and those skilled in the art can determine that they meet clinical standards.

[0067] The medicine of the present invention can be applied to the body by known means. For example, it can be delivered to the tissue of interest by intravenous systemic delivery or local injection. It can be applied optionally via intravenous, percutaneous, intranasal, mucosal or other delivery methods. Such application can be carried out via single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be applied in the present invention can vary depending on various factors to a great extent, such as target cells, biological types or their tissues, the general condition of the subject to be treated, the route of administration, the mode of administration, etc.

[0068] The drug administration subjects can be humans and non-human mammals, such as mice, rats, guinea pigs, rabbits, dogs, monkeys and gorillas, and are not specifically limited here.

[0069] The present invention is further explained by the following examples, but it does not constitute a limitation of the present invention. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention. The test methods in the following examples are generally carried out under conventional conditions. The nucleotide sequences used in the examples are as follows:

[0070]

[0071]

[0072] Example 1: Whole transcriptome sequencing results show that the expression of the immune regulatory molecule Tim-4 in DVT patients is significantly decreased compared with healthy subjects

[0073] T cell immunoglobulin and mucin domain molecule 4 (Tim-4) is a new type of immunomodulatory molecule discovered in 2004. Studies have shown that Tim-4 can inhibit macrophage inflammatory response and participate in the progression of various inflammatory-related diseases. We first collected peripheral blood samples from 6 healthy people and 6 patients with DVT, then isolated peripheral blood mononuclear cells, extracted total RNA, and performed whole transcriptome sequencing (including mRNA and non-coding RNA). The results are shown in Table 1. Tim-4 expression was significantly downregulated in DVT.

[0074] Table 1

[0075]

[0076] Note: [D]: DVT, DVT patients; [C]: Control, healthy people; FC: Fold change, difference fold.

[0077] Example 2: Tim-4 expression is reduced in DVT patients compared to healthy subjects

[0078] In order to verify the accuracy of the sequencing results, we further increased the number of clinical specimens, collected peripheral blood samples from 30 other healthy people and 30 patients with DVT, isolated peripheral blood mononuclear cells and extracted RNA, and used RT-PCR to detect the mRNA level of Tim-4. Figure 2 As shown in Figure 2, Tim-4 expression was significantly reduced in DVT patients compared with healthy controls ( Figure 1 ).

[0079] Example 3: Successful construction and verification of myeloid cell-specific Tim-4 knockout mice

[0080] In order to clarify the role of Tim-4 in DVT, we first commissioned Cysin (Suzhou) Biotechnology Co., Ltd. to successfully construct myeloid cell-specific Tim-4 knockout mice using Flox-Cre technology (lysM-Cre; Tim-4 fl / fl The genotype identification results are as follows Figure 2 A, Compared with wild-type mice, specific knockout mice lysM-Cre; Tim-4 fl / fl The mice were positive for lysM-Cre and homozygous for Loxp. The control mice were Tim-4 fl / fl The expression is lysM-Cre negative and Loxp homozygous ( Figure 2 A), and the knockout effect of the extracted mouse myeloid cells including peritoneal macrophages and bone marrow-derived macrophages was identified. The results of conventional PCR and western blot showed that the knockout effect was significantly different from that of the control mouse Tim-4 fl / fl In contrast, Tim-4 was expressed in the experimental group lysM-Cre; Tim-4fl / fl The expression was reduced in mice, with a significant knockout effect ( Figure 2 B, 2C).

[0081] The above mice were raised in the Experimental Animal Center of Shandong First Medical University (SPF grade) and bred to about 8 weeks of age for modeling and sampling. All operations complied with the ethical requirements of experimental animals, and various experimental operations were carried out under the review and approval of the Experimental Animal Ethics Committee of Shandong First Medical University (NO.2021-623).

[0082] Example 4: Myeloid cell-specific knockout of Tim-4 promotes thrombus formation

[0083] To clarify the function of abnormally expressed Tim-4 in DVT, we anesthetized control mice with Tim-4 fl / fl and experimental group lysM-Cre;Tim-4 fl / fl The inferior vena cava of mice was stripped and then ligated with surgical thread and sutured to establish a DVT model to explore the effect of myeloid cell-specific knockout of Tim-4 on deep vein thrombosis.

[0084] 1. Abdominal Ultrasound of Mice

[0085] Before treatment of mice, ultrasound examination was performed to assess thrombus size. fl / fl Compared with control mice, lysM-Cre;Tim-4 fl / fl The mice had larger thrombi ( Figure 3 A).

[0086] 2. Take photos of blood clots and spleen

[0087] After the mice were treated, the thrombus and spleen were separated, photographed, and weighed. fl / fl Compared with control mice, lysM-Cre;Tim-4 fl / fl The mice had larger blood clots and more enlarged spleens ( Figure 3 B).

[0088] 3. Histological staining.

[0089] The separated thrombus and spleen were fixed with paraformaldehyde, dehydrated, embedded, sliced, and HE stained to observe pathological changes. fl / fl Compared with control mice, lysM-Cre;Tim-4 fl / fl Mice had more thrombi and spleen inflammatory cell infiltration ( Figure 3 C).

[0090] Example 5: Bioinformatics analysis of non-coding RNAs that may target downregulation of Tim-4 expression

[0091] The present invention speculates that some non-coding RNAs may regulate the expression level of Tim-4, causing its expression to decrease in DVT. Among them, there is a very important regulatory relationship, the competitive endogenous RNA (ceRNA) regulatory relationship, that is, some lncRNAs are rich in sequences that complementarily bind to miRNAs and act as molecular sponges in cells, which are called ceRNAs. By competitively binding and blocking the complementary binding sites of miRNAs and target genes, miRNAs release the inhibition of target genes and indirectly upregulate the expression of target genes. Therefore, in order to screen this type of non-coding RNA, we first used the RNA interaction software RIsearch-2.0 to predict the regulatory relationship between Tim-4 and all lncRNAs, and then used multiple databases such as miRDB, DIANA, TargetScan, and miRanda to predict miRNAs that can target and regulate Tim-4. The results of the two parts were jointly analyzed with the results of the whole transcriptome chip, and the intersection was taken to draw the following lncRNA-microRNA-Tim-4 network diagram with potential ceRNA relationship ( Figure 4 ).

[0092] Example 6: miR-93-5p is upregulated in DVT, and this difference has the best statistical significance

[0093] The results of the whole transcriptome chip showed that among the microRNAs involved in the ceRNA network diagram, miR-93-5p was upregulated in DVT, and this difference had the best statistical significance. Therefore, we will further perform expression and functional verification analysis on miR-93-5p and lnc-RNF219-3:1 (which is downregulated in DVT) that forms a ceRNA relationship with it. The results are shown in Table 2.

[0094] Table 2

[0095]

[0096] Example 7: miR-93-5p is upregulated in DVT

[0097] To verify the accuracy of the miR-93-5p expression trend in the sequencing results, we further increased the number of clinical specimens and collected peripheral blood from 22 other healthy subjects and 22 DVT patients. After isolating mononuclear cells, we further confirmed the upregulation of miR-93-5p in DVT by real-time quantitative PCR.

[0098] Example 8: miR-93-5p can regulate Tim-4 expression

[0099] To verify whether miR-93-5p has function, we successfully overexpressed miR-93-5p (miR-93-5p mimics, i.e., mimics for miR-93-5p, abbreviated as 93-5p-m) in THP1, a human macrophage cell line, and HUVEC co-culture system ( Figure 6 A), overexpression of miR-93-5p inhibited Tim-4 expression ( Figure 6 B), upregulating the expression of thrombotic proteins von Willebrand factor (VWF) and tissue factor (TF) in HUVECs in the co-culture system, thereby promoting thrombosis ( Figure 6 C).

[0100] In contrast, after successful transfection of miR-93-5p inhibitor (i.e., antisense oligonucleotide targeting miR-93-5p, abbreviated as 93-5p-i) Figure 6 D), promotes Tim-4 expression ( Figure 6 E), down-regulating the expression of thrombotic proteins von Willebrand factor (VWF) and tissue factor (TF) in HUVECs in the co-culture system, thereby reducing thrombosis ( Figure 6 F).

[0101] Example 9: lnc-RNF219-3:1 expression is significantly downregulated in DVT patients

[0102] In order to verify the accuracy of the lnc-RNF219-3:1 expression trend in the sequencing results, we further increased the number of clinical specimens, collected peripheral blood from 30 other healthy subjects and 30 DVT patients, isolated mononuclear cells, and further confirmed by real-time quantitative PCR that lnc-RNF219-3:1 expression was significantly downregulated in DVT patients ( Figure 7 ).

[0103] Example 10: Overexpression of lnc-RNF219-3:1 can promote Tim-4 expression, inhibit miR-93-5p expression, and reduce the expression of prothrombotic related proteins

[0104] To verify whether the downregulated lnc-RNF219-3:1 in DVT patients has function, we successfully transfected the lnc-RNF219-3:1 overexpression plasmid into THP1 in the co-culture system of human macrophage cell line THP1 and human umbilical vein endothelial cell line HUVEC (plasmid purchased from Shanghai Boshang Biotechnology Co., Ltd. Figure 8 A), real-time quantitative PCR detection revealed that Tim-4 expression was upregulated ( Figure 8 B), while miR-93-5p was downregulated ( Figure 8C), and inhibited the expression of thrombotic proteins von Willebrand factor (VWF) and tissue factor (TF) in HUVEC, thereby reducing thrombosis ( Figure 8 D).

[0105] Example 11: Overexpression of lnc-RNF219-3:1 indirectly upregulates Tim-4 expression by inhibiting miR-93-5p, thereby inhibiting the thrombosis process

[0106] In order to verify whether lnc-RNF219-3:1 can act as a ceRNA and indirectly upregulate Tim-4 expression by reducing the amount of free miR-93-5p, we conducted a rescue experiment. In THP1 cells in a THP1 and HUVEC co-culture system, we successfully transfected the lnc-RNF219-3:1 overexpression plasmid (plasmid purchased from Shanghai Boshang Biotechnology Co., Ltd.) and added miR-93-5p inhibitors, namely antisense oligonucleotides ( Fig. 9 A), the results showed that overexpression of lnc-RNF219-3:1 alone could significantly upregulate the expression of Tim-4 and reduce the expression of prothrombotic factors. When further transfected with miR-93-5p inhibitor, Tim-4 expression decreased, while the expression of prothrombotic factors was upregulated ( Fig. 9 B, 9C, and 9D), therefore, overexpression of lnc-RNF219-3:1 indirectly upregulated Tim-4 expression by inhibiting miR-93-5p, thereby inhibiting thrombosis.

[0107] Example 12: Prediction of Tim-4, miR-93-5p, and lnc-RNF219-3:1 as diagnostic markers

[0108] We further analyzed the experimental results of Tim-4, miR-93-5p, and lnc-RNF219-3:1 by using the receiver operating curve (ROC). The results showed that the area under the ROC curve of Tim-4 was AUC = 1, p ≤ 0.0001 ( Fig.10 A), the area under the ROC curve of miR-93-5p AUC=0.8202, p=0.002773 ( Fig.10 B), the area under the ROC curve of lnc-RNF219-3:1 AUC=1, p≤0.0001( Fig.10C), therefore, we speculated that Tim-4, miR-93-5p, and lnc-RNF219-3:1 could serve as a group of very potential diagnostic markers for DVT, and that upregulating lnc-RNF219-3:1, upregulating Tim-4, or transfecting miR-93-5p inhibitors through plasmid transfection and downregulating the expression of miR-93-5p could be a group of very potential biological therapeutic targets for the treatment of DVT.

[0109] Nucleotide sequence of lnc-RNF219-3:1:

[0110]

[0111] The above embodiments are only for illustrating the technical concept and features of the present invention, and their purpose is to enable people familiar with the technology to understand the content of the present invention and implement it accordingly, and they cannot be used to limit the protection scope of the present invention. Any equivalent changes or modifications made according to the spirit of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of reagents for detecting the expression level of any one or more of lnc-RNF219-3:1 and its related biological elements in the preparation of products for screening, diagnosis, detection, monitoring or prognosis of deep vein thrombosis; The lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

2. The use according to claim 1, characterized in that: The reagents for detecting any one or more expression levels of lnc-RNF219-3:1 and its related biological elements include reagents for detecting the expression levels of genes encoding lnc-RNF219-3:1 and its related biological elements based on real-time fluorescence quantitative PCR, in situ hybridization, gene chips and gene sequencing, and / or reagents for detecting the expression levels of Tim-4 proteins based on immunodetection methods.

3. The use according to claim 1, characterized in that: The product includes primers, probes, (gene or protein) chips, nucleic acid membrane strips, detection kits, detection devices and detection equipment for detecting any one or more expression levels of lnc-RNF219-3:1 and its related biological elements.

4. A system for screening, diagnosis, detection, monitoring or prognosis of deep vein thrombosis, characterized in that: The system comprises: An acquisition module is configured to: obtain the expression level of any one or more of lnc-RNF219-3:1 and its related biological elements in the test sample of the subject; An evaluation module, configured to: evaluate and judge the disease condition of the subject according to the expression level of any one or more of lnc-RNF219-3:1 and its related biological elements obtained by the acquisition module; The lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

5. The system according to claim 4, characterized in that: The sample to be tested is a blood sample (including peripheral blood) or a cell sample (including peripheral blood mononuclear cells) of a subject.

6. Application of lnc-RNF219-3:1 and its related biological elements as targets in the preparation and / or screening of deep vein thrombosis drugs; in, The lnc-RNF219-3:1 related biological elements include miR-93-5p and Tim-4.

7. Use of substances that promote the expression of lnc-RNF219-3:1 or increase its activity in any one or more of the following: a) inhibiting the expression of miR-93-5p or preparing a product that inhibits the expression of miR-93-5p; b) promoting the expression of Tim-4 or preparing a product that promotes the expression of Tim-4; c) Inhibiting the expression of prothrombotic factors or preparing products that inhibit the expression of prothrombotic factors; d) Products for the prevention and / or treatment of deep vein thrombosis.

8. The use according to claim 7, characterized in that Substances that promote the expression of lnc-RNF219-3:1 or increase its activity include overexpression plasmids and overexpression viruses for lnc-RNF219-3:1 and substances required for the CRISPR-SAM system.

9. The use according to claim 7, characterized in that: The thrombotic factors include the thrombotic proteins hemophilia factor and tissue factor.

10. The use according to claim 7, characterized in that: The product is a drug or an experimental reagent for non-medical use.

Citation Information

Cited By

  • Application of NAT10 and related biomolecules thereof in diagnosis and treatment of deep vein thrombosis

    CN121406766A